Targeted Therapy and Immunotherapy for Melanoma in Japan

Abstract

Opinion statementMelanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution of systemic therapies for advanced melanoma, access to innovative agents is still restricted in many countries. This review article aimed to describe the epidemiology and current status of systemic therapies for melanoma in Japan, where melanoma is rare, but access to innovative agents is available. Acral and mucosal melanomas, which are common in Asian populations, predominantly occur in sun-protected areas and share several biological features. Both the melanomas harbor KIT mutation in approximately 15% of the cases; BRAF or NRAS mutation is found in approximately 10–15% of acral melanoma, but these mutations are less frequent in mucosal melanoma. Combined use of BRAF and MEK inhibitors is one of the standards of care for patients with advanced BRAF-mutant melanoma. In patients with melanoma harboring KIT mutation in exon 11 or 13, KIT inhibitors can be a treatment option; however, none of them have been approved in Japan. Immune-checkpoint inhibitors are expected to be less effective against acral and mucosal melanomas because their somatic mutation burden is lower than those in non-acral cutaneous melanomas. A recently completed phase II trial of nivolumab and ipilimumab combination therapy in 30 Japanese patients with melanoma, including seven with acral and 12 with mucosal melanoma, demonstrated an objective response rate of 43%. Regarding oncolytic viruses, canerpaturev (C-REV, also known as HF10) and talimogene laherparepvec (T-VEC) are currently under review in early phase trials. In the adjuvant setting, dabrafenib plus trametinb combination, nivolumab monotherapy, and pembrolizumab monotherapy were approved in July, August, and December 2018 in Japan, respectively. However, most of the adjuvant phase III trials excluded patients with mucosal melanoma. A phase III trial of adjuvant therapy with locoregional interferon (IFN)-β versus surgery alone is ongoing in Japan (JCOG1309, J-FERON), in which IFN-β is injected directly into the site of the primary tumor postoperatively, so that it would be drained through the untreated lymphatic route to the regional node basin. After the recent approval of these new agents, the JCOG1309 trial will be revised to focus on patients with stage II disease. In conclusion, acral and mucosal melanomas have been treated based on the available medical evidence for the treatment of non-acral cutaneous melanomas. Considering the differences in genetic backgrounds and therapeutic efficacy of immunotherapy, specialized therapeutic strategies for these subtypes of melanoma should be established in the future.

Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody

“…Several studies have shown that the curative effect of the PD-1 antibody combined with chemotherapy, targeted drugs, and multiple immune checkpoint drugs was better than that of the administration of a single drug. The effect of getting twice the result with half the effort was obtained [37][38][39][40][41][42] . It should be noted that the therapy with PD-1 or PD-L1 antibody is known to be effective mainly through the immunological mechanism playing the antitumor role;…”

Mesothelioma, a Review of Current Guidelines

“…Five of 25 patients (20%) had a partial response (objective response rate of 20%) and 13 (52%) patients had stable disease. Additionally, there was a maintained clinical benefit, with a median duration of response 12.0 months (95% CI: 3.7 not reached) [32,33]. The NivoMes Mesothelioma, a Review of Current Guidelines DOI: http://dx.doi.org/10.5772/intechopen.93569 study, which evaluated nivolumab in unselected patients with previously treated mesothelioma reported response rates of 28%.…”

“…Subgroup analysis in the PD-L1-positive population (cutoff > 5%) showed a response rate of 14% [34]. Novel vaccine approaches using MPM neoantigens identified by gene sequencing are also entering clinical trial on the basis of early animal studies [33].…”

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review

“…Nearly two-thirds of AM was diagnosed at stage II or above, while only approximately one-third of cutaneous melanoma was diagnosed at stage II or above. Therefore, most patients have developed distant metastasis when diagnosed with AM, and systemic treatment for advanced AM is of great significance ( 3 ).…”